The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

(NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, today released the findings of their 2024 U.S. state and local End-of-Year Rates and Rules Report. It ...

“With the Humanizer technology in SurgeGraph Vertex, we’re not just updating our product; we’re solving one of the most pressing issues in AI-assisted content writing,” said Sara Salim ...

The VERTEX 80/80v optics design allows PEAK flexibility and PEAK instrument performance at the same time. The unique Bruker Optics DigiTect ™ technology ensures PEAK signal-to-noise ratio ...

Vertex Pharmaceuticals Inc. will work with ... Orna acquired Cambridge-based ReNAgade in 2024 to access the company’s technology for delivering RNA medicines. Orna had previously been focused ...

Vertex Pharmaceuticals (VRTX ... Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 1.24%. The drugmaker's shares have seen a decrease of ...

As Chief Technology Officer, Sal leads the company’s technology strategy, software engineering and innovation roadmap to accelerate growth. He joined Vertex in 2021 after 30 years of technology and ...